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Summary
Objectives: Transoral robotic surgery (TORS) is an innovative surgical technique indicated for
resection of selected head and neck cancers. The authors report their experience and discuss
the indications, advantages and disadvantages of this technique.
Materials and methods: Seventeen patients were operated by TORS in the Limoges University
Hospital ENT department between March 2010 and January 2011.
Results: Tumour sites were the aryepiglottic fold (n = 3), piriform sinus (n = 2), lateral pha-
ryngeal wall (n = 3), posterior pharyngeal wall (n = 2), base of tongue (n = 3), vallecula (n = 1),
epiglottis (n = 2) and arytenoid (n = 2). One patient had two primary sites treated by TORS.
This series comprised two stage I (11.7%), seven stage II (41.2%), six stage III (35.4%) and two
stage IVa tumours (11.7%). Mean TORS set-up and operating times were 20.5 and 39.7minutes,
respectively. No major intraoperative complication was observed. One patient was reoperated
on D5 for bleeding. Fifteen patients had clear surgical margins. Swallowing was restored on
D2 for nine patients. The mean length of hospital stay was 10 days. Seven patients received
adjuvant radiotherapy, seven patients were treated by chemoradiotherapy and three patients
were submitted to simple clinical surveillance.
Conclusion: TORS appears to provide new treatment options for head and neck cancers by
extending the indications for endoscopic resection for selected cases of head and neck cancers.
It allows effective cancer resection under excellent operating conditions with low morbidity and
improved functional recovery. This new treatment modality needs to be evaluated in relation
to other open surgery, endoscopic laser and chemoradiotherapy techniques.
. All© 2011 Elsevier Masson SAS∗ Corresponding author. Tel.: +33 5 55 05 62 39;
ax: +33 5 55 05 62 87.
E-mail address: aubryorl@aol.com (K. Aubry).
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ntroductionransoral robotic surgery (TORS) was described for the ﬁrst
ime in 2006 by Weinstein’s team at the University of Penn-
ylvania successively on animals, cadavers, and then in
linical practice initially on oropharyngeal tumours and then
served.
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mFigure 1 The da Vinci Surgical System (Intuitive Surgical Inc.,
Sunnyvale, California): console; robot; video column.
supraglottic tumours [1—7]. This surgical technique has been
developed in France since 2008. It is an innovative tech-
nique, currently under evaluation by the Groupe franc¸ais
de chirugie télé-robotisé (French Robotic Surgery Group).
We report our experience of TORS for the treatment of
head and neck cancers since March 2010.
Materials and methods
This series comprises all patients managed for head and neck
cancer by TORS between March 2010 and January 2011. An
Feyh-Kastenbauer (FK) retractor (Gyrus Medical Inc., Maple
Grove, MIN) and a 30◦ endoscope were used in all patients
during the initial panendoscopy to assess mouth opening
and the feasibility of TORS. Staging assessment including
neck, chest and abdomen CT scan, was performed in each
patient and staging was performed according to the TNM
classiﬁcation. Each patient was discussed at a multidisci-
plinary consultation meeting during which it was decided
to perform TORS. Unilateral or bilateral neck dissection of
group I to IV nodes, according to tumour site, was per-
formed during the same operating time, when indicated.
The ﬁrst step of TORS consisted of insertion of the FK retrac-
tor, taking care to protect the patient’s teeth with molded
thermoplastic sheeting. All surgical procedures were ﬁlmed
and stored in a database. The da Vinci Surgical System
(Intuitive Surgical Inc., Sunnyvale, California) surgical robot
was used, comprising three elements: (i) the console, (ii)
the patient-side cart with three robotic arms: the central
arm holding the dual 8.5mm 30◦ lenses and two side arms
for grasping and dissection instruments and (iii) the video
column, allowing the operation to be followed by the assis-
tant seated at the patient’s head and all of the operating
room (Fig. 1). The robot was guided at an angle of 30◦ to
the axis of the operating table to ensure optimal position-
ing of these arms. The grasping instruments used on the
two side arms were a 5mm endowrist Maryland dissector or
Bakey dissector (Intuitive Surgical, Inc., Sunnyvale, Califor-
nia) and a 5mm monopolar spatula for surgical dissection.
The surgeon was seated at the console and the assistant
was seated at the patient’s head to monitor the operative
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ite and good conduct of the operation, to retract tissues
o facilitate dissection, and to evacuate smoke released by
onopolar electrosurgery. The assistant played an essential
ole to resolve any conﬂicts and adequately reposition the
obotic arms during dissection. Vessels exposed during dis-
ection were clipped before section. The ﬁrst tracheal rings
ere systematically exposed by performing isthmectomy in
rder to facilitate emergency tracheotomy, when indicated.
t the end of the operation, Floseal® (Baxter, Bloomington,
ndiana) haemostatic gel was applied to the wound. Note
hat the head and neck surgery table used for neck dissec-
ions was maintained sterile during TORS to allow emergency
aemostasis or tracheotomy or conversion to open surgery.
s in conventional cancer surgery, the operative specimen
as labelled and frozen section examination of surgical mar-
ins was performed. Resection was systematically continued
ntil histological examination demonstrated clear surgical
argins. Intravenous corticosteroid therapy was initiated at
he end of operation at a dose of 3mg/kg/day for 2 days
nd was then tapered over 5 days. Adjuvant therapy was
iscussed at multidisciplinary consultation meetings, based
n the pTNM classiﬁcation.
All charts were reviewed by recording the following
ata: age, gender, tumour site, histology, cTNM stage,
obot set-up time, tumour resection time, whether or not
racheotomy was performed, insertion of a nasogastric
ube or gastrostomy, time to resumption of oral feeding,
TNM stage, surgical margins, mean length of hospital stay,
omplications, adjuvant treatment and follow-up.
esults
eventeen patients, three females and 14 males, with a
ean age of 60.3 years (range 43—80) were treated for
quamous cell carcinoma of the head and neck by minimally
nvasive robotic surgery between March 2010 and January
011. All patients had a history of smoking and/or drink-
ng. Tumour sites were the aryepiglottic fold (n = 3), piriform
inus (n = 2), lateral pharyngeal wall (n = 3), posterior pha-
yngeal wall (n = 2), base of tongue (n = 3), vallecula (n = 1),
piglottis (n = 2) and arytenoid (n = 2) (Table 1). This series
omprised two stage I (11.7%), seven stage II (41.2%),
ix stage III (35.4%) and two stage IVa (11.7%) tumours.
wo groups were distinguished within this series. Group I
as deﬁned by management of one or two tumour sites
reated exclusively by TORS; this group was composed of
5 patients, including one patient (case No. 17) with two
rimary tumours (T2 tumour of the left arytenoid and T2
umour of the epiglottis) and one patient (case No. 11)
as managed for a third tumour (T2 tumour of the lateral
haryngeal wall). Group II was managed by a combination
f TORS and conventional open surgery with placement of
ﬂap; this group was composed of two patients, one of
hom (case No. 2) presented two primary tumours (T1
umour of the posterior pharyngeal wall treated by TORS
nd T2 tumour of the ﬂoor of the mouth treated by marginal
andibulectomy and infrahyoid ﬂap), while the other (case
o. 14), with a history of T3 tumour of the left tonsil treated
y surgery and adjuvant radiotherapy, was treated for a
3N0M0 second tumour arising in the contralateral tonsil
ith extension to the base of the tongue posteriorly and
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Table 1 Clinical data and results.
Case Tumour site cTNM
(Stage)
Robot
set-up
time
(min)
Robotic
operating
time (min)
Trach. NG tube Return of
swallowing
(days)
Surgical
margins
pTNM LHS
(days)
Adjuvant
therapy
1 Lateral
pharyngeal
wall
T2N1M0
(Stage III)
30 35 — — 2 — pT2N+CE+
PNI−
E−
4 CR
2 Posterior
pharyngeal
wall
T1N1M0
(Stage III)
50 30 — + 7 — pT1N−
PNI−
E−
10 R
3 Piriform
sinus
T1N1M0
(Stage III)
20 45 — — 2 — pT1N+CE+
PNI−
E−
5 CR
4 Base of
tongue
T2N0M0
(Stage II)
20 25 — + 3 — pT2N+CE−
PNI−
E−
7 R
5 Aryepiglottic
fold
T2N0M0
(Stage II)
27 60 + + 10 — pT2N+CE−
PNI+
E−
25 CR
6 Vallecula T2N0M0
(Stage II)
27 57 — — 2 — pT2N−
PNI−
E−
4 R
7 Posterior
pharyngeal
wall
T3N0M0
(Stage III)
15 90 — + 8 Uncertain pT3N−
PNI−
E−
17 R
8 Aryepiglottic
fold
T2N0M0
(Stage II)
10 55 — — 2 — pT2N+CE−
PNI−
E−
4 R
9 Aryepiglottic
fold
T1N0M0
(Stage I)
32 18 — — 2 — pT1
PNI−
E−
3 R
10 Piriform
sinus
T1N2bM0
(Stage IVa)
30 25 — — 2 — pT1N+CE+
PNI−
E−
5 CR
11 Lateral
pharyngeal
wall
T2N0M0
(Stage II)
15 35 — — 2 — pT2
PNI−
E−
4 S
12 Base of
tongue
T3N2bM0
(Stage IVa)
20 90 — + Gastrostomy — pT3N+CE+
PNI−
E−
13 CR
13 Epiglottis T2N0M0
(Stage II)
10 25 — — 2 — pT2N+CE−
PNI+
E−
9 CR
14 Base of
tongue
T3N0M0
(Stage III)
10 20 + + 21 — pT3
PNI−
E−
30 S
15 Arytenoid T1N0M0
(Stage I)
13 10 — — 2 — pT1N−
PNI−
E−
7 S
16 Lateral
pharyngeal
wall
T2N1M0
(Stage III)
10 30 — + 7 — pT2N+CE−
PNI−
E+
10 R
17 Arytenoid +
Epiglottis
T2N0M0
T2N0M0
(Stage II)
10 25 — + Gastrostomy Carcinoma
in situ
pT2N+R+
PNI+
E+
13 CR
Trach.: tracheotomy; NG: nasogastric; N−: no lymph node metastasis; N+: lymph node metastasis; CE: capsular effraction; PNI: perineural
invasion; E: vascular emboli; CR: chemoradiotherapy; R: radiotherapy; S: surveillance; LHS: length of hospital stay.
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the retromolar trigone anteriorly. Resection of this tumour
was initiated by TORS to detach the tumour from the base
of the tongue, and was then continued by conventional oral
surgery with placement of a pectoralis major ﬂap to cover
the exposed mandibular bone in the retromolar region and
oropharyngeal defect. Unilateral or bilateral neck dissec-
tion was performed in 14 of the 17 patients during the
initial surgery, depending on tumour site (cases No. 11 and
14 had already undergone neck dissection during previous
operations and case No. 9 was an 80-year-old woman with
a cT1N0M0 tumour of the right arytenoid, in whom the mul-
tidisciplinary consultation meeting decided not to perform
neck dissection). No major intraoperative complication was
observed, with only one case of pharyngocervical commu-
nication occurring during TORS in a patient managed for a
T2 tumour of the lateral pharyngeal wall, undergoing neck
dissection during the same operation. Mucosal suture was
performed with the robot, a nasogastric tube was placed
for 7 days, and no postoperative complication was observed.
No patient required conversion to open surgery to ensure
complete tumour resection. Mean robot set-up and surgical
resection times were 20.5 [± 11] and 39.7 [± 23.54] minutes,
respectively. Most tumours were resected in en bloc (Fig. 2)
except for one tumour (case No. 12) which was fragmented
due to its size in order to allow adequate visualization during
resection. Frozen section examination of the operative spec-
imen was performed in all patients to study surgical margins.
Deﬁnitive margins were negative for 15 patients, uncertain
(due to the presence of coagulation artefacts) in one patient
(case No. 7) and with the presence of carcinoma in situ in one
patient (case No. 17). Three patients had perineural invasion
and two patients presented vascular tumour emboli. Neck
dissection was performed in 14 patients, revealing four N−,
ﬁve N+ CE− and ﬁve N+ CE+. All postoperative complications
were entered into the Groupe franc¸ais de chirugie télé-
robotisé (French Robotic Surgery Group) national database:
an immediate postoperative neck haematoma requiring sur-
gical drainage with no postoperative consequence and a case
of intraoral bleeding on D5 requiring endoscopic cauteri-
zation under general anaesthesia without transfusion. No
infectious complications were observed.
Two tracheotomies were performed in this series, one in
group I in a context of respiratory distress due to imme-
diate postoperative laryngeal oedema and one in group II,
which was expected in view of oropharyngeal reconstruc-
tion by a pectoralis major myocutaneous ﬂap; extubation
was performed on D7 and D10, respectively.
Nine of the 17 patients, ﬁve with pharyngeal tumours and
four with supraglottic tumours, did not require a nasogastric
tube and resumed normal oral feeding on D2. A nasogas-
tric tube was inserted at the end of the surgical procedure
in eight of the 17 patients, six with pharyngeal tumours
and two with laryngeal tumours (6/15 of group I and 2/2
of group II) with return of swallowing after an average of
9 days (range: 3—21 days) for six patients (D7 in group I
and D14 in group II). According to tumour site, return of
swallowing was observed after an average of 3.6 days after
partial laryngopharyngectomy or supraglottic laryngectomy
and 5.6 days after partial pharyngectomy. Two patients, one
managed for a T3 tumour of the base of the tongue and the
other with two laryngeal tumours treated by TORS, required
insertion of a gastrostomy feeding tube while continu-
u
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ng swallowing rehabilitation. No cases of aspiration with
ulmonary infectious complications were observed. The
ean length of hospital stay was 10 days [± 7.72]: 8.6 days
n group I and 20 days in group II. Seven patients received
djuvant radiotherapy, seven patients were treated by
hemoradiotherapy and three patients were submitted to
imple clinical surveillance. With a mean follow-up of
.5months [± 3.9], no case of disease progression, local or
egional recurrence or metastasis has been observed.
iscussion
dvantages and disadvantages of Transoral robotic
urgery
inimally invasive TORS, comprising 3D HD vision, image
agniﬁcation, tremor ﬁltration and 180◦ mobility in all
lanes of the distal articulated extremity of endowrist
nstruments, provides many advantages, such as perfect
isualization of zones that were previously difﬁcult to access
y direct laryngoscopy, such as the base of the tongue [8].
ransoral laser surgery with an operating microscope does
ot provide the same advantages, including the angle of
ision obtained by the dual 30◦ eyepieces of the robot and
he possibilities of lateral resection conferred by the use of
ndowrist instruments.
One of the possible drawbacks of TORS consists of
onﬂicts between robotic arms during surgery, sometimes
equiring several repositionings. These conﬂicts essentially
epend on the patient’s anatomy and the tumour site. The
bsence of tissue resistance for the surgeon seated at the
onsole can also constitute a disadvantage during the ﬁrst
ORS procedures, but the surgeon can learn to ignore this
spect with experience. A perfect knowledge of regional
natomy and an extensive experience of open surgery by a
enior surgeon are therefore essential when using the robot.
ndications and contraindications of Transoral
obotic surgery
he indications of TORS at the present time are essentially
mall or medium-sized (T1 to T2) lesions localized in the
ropharynx, supraglottic part of the larynx and hypophar-
nx [9—11]. However, the indications for this innovative
urgery are currently being extended to glottic tumours and
arger lesions, such as T3 and T4 tumours [12—14]. Sys-
ematic veriﬁcation of sufﬁcient mouth opening allowing
dequate exposure of the tumour, by using an FK retrac-
or and a 30◦ endoscope during the initial panendoscopy,
s generally an essential prerequisite to the indication of
ORS. There are two main contraindications to TORS related
o endoscopic exposure of the tumour, which depends on
natomical factors and tumour stage. Anatomical char-
cteristics preventing adequate transoral exposure of the
perative site are essentially retrognathia, limited mouth
pening and reduced mobility of the neck [10,11]. In our
nit, we have decided not to use TORS for localized tonsil-
ar tumours, without extension to the base of the tongue,
ue to the excess cost compared to conventional transo-
al surgery and the absence of any postoperative functional
294 K. Aubry et al.
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: nasopharyngoscopy on postoperative day 9.
eneﬁts. In the present series, composed of various tumour
ites, hypopharyngeal sites, especially the piriform sinus,
as found to be the most difﬁcult site for TORS resection
ue to the narrow dimensions of this region. According to
ark et al., invasion of the anterior angle and base of the
iriform sinus constitutes a contraindication to TORS [10].
perating time
nalysis of operating times showed that robot set-up time
aried according to the tumour site and the surgeon’s expe-
ience, but was generally 10minutes after an experience
f about 10 cases, which is comparable to that reported
n the literature [8,10]. The mean surgical resection time
n this series was 39.7minutes. This time depends on sev-
ral parameters: the surgeon’s experience, exposure and
he presence or absence of conﬂicts between robotic arms,
umour site, tumour size and the number of resections
erformed to achieve clear margins [8,10,15]. TORS may
herefore sometimes allow a shorter operating time than
hat of conventional open surgery, which could be an advan-
age in elderly or frail patients, by decreasing the general
naesthesia time. This potential advantage needs to be con-
rmed by the ongoing multicentre prospective study.
ntraoperative complications
nly one intraoperative complication was observed: a case
f pharyngocervical communication. This complication was
ecently reported by Moore et al., who considered that neck
issection concurrent with TORS was a risk factor for pharyn-
ocervical communication, but showed that, when it is
losed immediately, it does not constitute a major risk factor
or pharyngocutaneous ﬁstula and does not delay adju-
ant therapy [16]. No intraoperative bleeding was observed
nd no conversion was required in our series. However,
he patient is systematically informed before the opera-
ion about these risks. As a precaution, a sterile head and
eck surgery table is always kept available during TORS if
mergency haemostasis or open conversion needs to be per-
ormed.
i
t
m
tction at the end of the procedure; B: tumour of the epiglottis;
istological results
s in any form of cancer surgery, the objective of TORS
s to achieve free en bloc resection with clear margins.
owever, the operative specimen sometimes needs to be
ragmented in order to obtain adequate surgical vision,
s during endoscopic laser laryngeal surgery [17]. Frozen
ection examinations must be performed systematically
o conﬁrm histologically complete resection. Use of the
onopolar spatula and the coagulation artefacts and retrac-
ion of the wound edges that it induces sometimes makes
t difﬁcult to analyse the surgical margins, particularly on
rozen sections, but these disadvantages can now be over-
ome by the recent use of a robot combined with laser, when
vailable [18].
unctional results
he functional results observed in group I were better than
hose observed after conventional surgery due to the almost
omplete absence of tracheotomy and rapid resumption
f oral feeding. The functional results in group II were
imilar to those observed after conventional surgery, as
wo patients required reconstruction by a ﬂap. By avoiding
pening of the pharyngeal mucosa and disinsertion of the
uscles, TORS allows preservation of the tissues and appears
o provide better functional rehabilitation with decreased
orbidity due to the almost systematic absence of tra-
heotomy and rapid resumption of oral feeding regardless
f the laryngeal or pharyngeal site of the tumour [19—23].
owever, there is still a risk of postoperative pharyngolaryn-
eal oedema and we believe that systematic preparation of
racheotomy by performing isthmectomy during neck dissec-
ion, corticosteroid therapy initiated intraoperatively and
ostoperative surveillance in intensive care are essential
recautions. Some authors propose prolonged intubation for
4 to 72 h or tracheotomy depending on the site and the
ype of tumour resection [1,10]. Each case must therefore be
ssessed according to site, tumour stage, and the patient’s
ge, general status and comorbidities.
In this series, return of swallowing and resumption of
ral feeding were observed on D2 in nine patients and D9
n six patients and a gastrostomy tube was required in
wo patients. These results therefore appear to indicate
ore rapid swallowing rehabilitation after TORS compared
o open surgical techniques. Some authors report better
of 1
[
[
[
[
[
[
[
[
[
[
[
[
[
[Transoral robotic surgery for head and neck cancer: A series
results on swallowing and a lower gastrostomy rate com-
pared to chemoradiotherapy alone [24,25].
The use of TORS combined with conventional transoral
surgery in one patient treated for a second tonsillar tumour
contralateral to the ﬁrst, in which the theoretical indica-
tion was transmandibular buccopharyngectomy avoided the
need for mandibulotomy, by using TORS to resect the tumour
invading the base of the tongue, thereby decreasing the risks
of radiation osteonecrosis.
TORS also appeared to be useful to treat subsequent
tumours for which access by conventional surgery and the
postoperative course are often difﬁcult due to the presence
of radiation-induced ﬁbrosis of the neck [22].
The observed improvement of functional rehabilitation
in this series was accompanied by a reduction of the
mean length of hospital stay compared to the conventional
open surgery (partial laryngopharyngectomy or segmental
mandibulectomy) that would have been proposed to these
patients in the absence of the robot, as reported in other
publications [15,26].
Follow-up
No case of disease progression or local or distant recurrence
was observed in this series, but follow-up is insufﬁcient to
allow a reliable analysis. The long-term oncological results
therefore need to be deﬁned. A recent publication by White
et al., based on a series of 89 patients (24 stage I and II
and 65 stage III and IV) reported a 2-year survival of 86.5%
[27]. Weinstein et al. did not observe any signiﬁcant differ-
ence in terms of recurrence rate in a series of 47 stage III
patients with a mean follow-up of 26.6 months compared to
conventional surgery [24].
Conclusion
TORS appears to constitute a useful surgical alternative to
conventional open surgery in selected indications, some-
times allowing a reduction of postoperative morbidity and
improved functional rehabilitation. In the future, the cur-
rent indications will certainly be extended as a result of
probable technical improvements including miniaturization
of instruments. Studies on quality of life, speech rehabili-
tation, swallowing and long-term oncological results will be
essential in order to objectively compare TORS with other
surgical and nonsurgical treatments.
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